Enochian Biosciences, Inc. (ENOB)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.5600 |
| Open | 2.6000 |
| Bid | 2.4200 x 900 |
| Ask | 2.7600 x 1100 |
| Day's Range | 2.4000 - 2.5200 |
| 52 Week Range | 1.4200 - 13.7800 |
| Volume | |
| Avg. Volume | 476,970 |
| Market Cap | 127.938M |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6650 |
| Earnings Date | May 11, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Enochian BioSciences Appoints Dr. Richard Whitley As Senior Scientific Advisor
LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Company’s Senior Scientific Advisor. A Distinguished Professor of Pediatrics at UAB, Dr. Whitley brings decades of virology research experience to the Company, including clinical research experience to develop antiviral therapies. "We are incredibly excited to bring on Dr. Whitley
- The Wall Street Journal
Enochian Biosciences Finds Falsified Data in Study of Covid-19 Treatment
The allegations are the latest against biotech wizard Serhat Gumrukcu who was indicted in a murder-for-hire case in recent months.
- GlobeNewswire
Enochian BioSciences Announces Findings From A Rigorous Internal Review of Scientific Data
LOS ANGELES, July 01, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—In recent days, Enochian BioSciences (the Company) has conducted a rigorous internal review of scientific data to give partners and investors a clear understanding of the Company’s pipelines. The results of this investigation verified key primary data for the Company’s HIV and cancer pipelines. The investigation also verified the primary data from an animal model with intravenous delivery of a potential treatment for COVID-19 that was
